Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
IBD
S1P1 receptor modulators
VTX-002
etrasimod
inflammatory bowel disease
ozanimod
ulcerative colitis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
received:
05
07
2023
revised:
24
07
2023
accepted:
28
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that negatively impacts patients' quality of life. In the last decades, the therapeutic options available for the management of patients with moderate to severe UC have increased significantly, including not only biological drugs but also small molecules. However, there is a persistent need to develop new drugs that act on new targets while minimizing the risk of adverse events. Sphingosine-1-phosphate (S1P) is a membrane-derived lysophospholipid. The S1P gradient between tissues and the circulatory system has a key role in regulating the trafficking of immune cells as autoreactive B and T lymphocytes. S1P receptor modulators could be a safe and efficacious alternative mechanism for reducing inflammation in immune-mediated disorders, including UC, by reducing lymphocyte egress from the lymph nodes to the bloodstream. Several S1P receptor modulators have been developed and tested in UC. Ozanimod is already approved by Food and Drug Administration (FDA) and European Medical Agency (EMA), while etrasimod and VTX002 are still under approval. Oral administration route, rapidity and reliable safety profile are the main advantages of this class of drugs. The aim of this review is to summarize the available evidence for the efficacy, safety, and pharmacokinetics of ozanimod, etrasimod, and VTX002 in UC.
Identifiants
pubmed: 37568417
pii: jcm12155014
doi: 10.3390/jcm12155014
pmc: PMC10419826
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2021 Sep 30;385(14):1280-1291
pubmed: 34587385
Inflamm Bowel Dis. 2019 Jan 10;25(2):270-282
pubmed: 30165490
Nat Rev Immunol. 2008 Oct;8(10):753-63
pubmed: 18787560
Expert Rev Gastroenterol Hepatol. 2020 Jan;14(1):47-54
pubmed: 31874053
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
pubmed: 20064142
Expert Rev Clin Immunol. 2017 Jul;13(7):693-703
pubmed: 28164724
J Crohns Colitis. 2022 Jan 28;16(1):2-17
pubmed: 34635919
Front Pharmacol. 2019 Sep 19;10:1085
pubmed: 31607926
N Engl J Med. 2016 May 5;374(18):1754-62
pubmed: 27144850
Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):351-366
pubmed: 35165437
Br J Pharmacol. 2016 Jun;173(11):1778-92
pubmed: 26990079
Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38-39:101617
pubmed: 31327399
Mucosal Immunol. 2017 Jan;10(1):162-171
pubmed: 27049060
Gastroenterol Hepatol (N Y). 2019 Dec;15(12):656-665
pubmed: 31892912
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45
pubmed: 26284562
Nutrients. 2023 Feb 21;15(5):
pubmed: 36904079
Gastroenterology. 2012 Feb;142(2):257-65.e1-3
pubmed: 22062358
Gastroenterology. 2020 Apr;158(5):1450-1461
pubmed: 31945371
Int J Mol Sci. 2023 Jan 11;24(2):
pubmed: 36674974
Gut Liver. 2023 Jun 9;:
pubmed: 37291901
Nat Rev Drug Discov. 2009 Apr;8(4):297-307
pubmed: 19300460
Gastroenterology. 2004 May;126(6):1504-17
pubmed: 15168363
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):819-828
pubmed: 32553149
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Lancet. 2021 Jun 19;397(10292):2372-2384
pubmed: 34090625
Nat Rev Immunol. 2011 Jun;11(6):403-15
pubmed: 21546914
Pharmacol Rev. 2008 Jun;60(2):181-95
pubmed: 18552276
Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101492
pubmed: 33642219
J Crohns Colitis. 2021 Jun 22;15(6):950-959
pubmed: 33475734
Front Pharmacol. 2019 Mar 13;10:212
pubmed: 30930775
Inflamm Bowel Dis. 2018 Nov 29;24(12):2527-2542
pubmed: 29788338
Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8
pubmed: 21339489
Clin Transl Gastroenterol. 2016 Jan 07;7:e135
pubmed: 26741065
Lancet. 2022 Jun 4;399(10341):2113-2128
pubmed: 35644166
Dig Liver Dis. 2019 Mar;51(3):327-334
pubmed: 30555013
J Crohns Colitis. 2021 Jul 5;15(7):1120-1129
pubmed: 33438008
Mol Pharmacol. 2016 Jan;89(1):176-86
pubmed: 26494861
Front Microbiol. 2022 Sep 26;13:999001
pubmed: 36225386
J Clin Invest. 2015 Apr;125(4):1379-87
pubmed: 25831442
J Clin Pharmacol. 2017 Aug;57(8):988-996
pubmed: 28398597
Clin Pharmacol Drug Dev. 2018 Mar;7(3):263-276
pubmed: 28783871
Autoimmun Rev. 2017 May;16(5):495-503
pubmed: 28279838
Lupus. 2020 Dec;29(14):1902-1913
pubmed: 33115374
Lancet Neurol. 2019 Nov;18(11):1021-1033
pubmed: 31492652
J Crohns Colitis. 2023 Jan 27;17(1):1-27
pubmed: 36005814
Lancet. 2023 Apr 8;401(10383):1159-1171
pubmed: 36871574
Nutrients. 2023 Jun 29;15(13):
pubmed: 37447285
J Pharmacol Exp Ther. 2019 Jun;369(3):311-317
pubmed: 30872391
Nutrients. 2023 Jun 14;15(12):
pubmed: 37375647
Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640
pubmed: 29125718
J Exp Clin Cancer Res. 2020 Nov 23;39(1):253
pubmed: 33225975
Gastroenterology. 2020 Feb;158(3):550-561
pubmed: 31711921
Lancet. 2014 Dec 6;384(9959):2036-45
pubmed: 25127208
Gut. 2017 Feb;66(2):199-209
pubmed: 27856614
Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):879-95
pubmed: 27249325
J Autoimmun. 2017 Dec;85:103-116
pubmed: 28711286
Aliment Pharmacol Ther. 2018 Dec;48(11-12):1174-1185
pubmed: 30378141
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Biochim Biophys Acta. 2002 May 23;1582(1-3):94-9
pubmed: 12069815
Nutrients. 2023 Feb 28;15(5):
pubmed: 36904207
Drugs. 2020 Jun;80(8):841-848
pubmed: 32385738
Lancet Neurol. 2019 Nov;18(11):1009-1020
pubmed: 31492651
Annu Rev Immunol. 2012;30:69-94
pubmed: 22149932